• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cardinal Health announces the merger of its Outcomes™ business into Transaction Data Systems and related partnership

    6/5/23 9:00:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care
    Get the next $CAH alert in real time by email

    Cardinal Health's Outcomes™ business will combine with Transaction Data Systems to offer improved patient engagement and clinical pharmacy solutions, expanding connections between payers and pharma to its nationwide pharmacy network

    DUBLIN, Ohio, June 5, 2023 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced it has signed a definitive agreement to contribute its Outcomes™ business to Transaction Data Systems (TDS), a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a minority stake in the combined entity. Under the terms of the agreement, Cardinal Health's pharmaceutical segment CEO, Debbie Weitzman, will be appointed to the TDS board of directors. 

    Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. (PRNewsfoto/Cardinal Health)

    The transaction will create a broad, integrated offering of pharmacy workflow software with patient engagement and clinical solutions to serve the patient, pharmacy, payer, and pharmaceutical company ecosystem, including one of the nation's largest networks of 40,000 retail, chain and grocery pharmacies.  

    TDS's existing portfolio of clinical pharmacy solutions includes the Rx30 and Computer-Rx pharmacy management systems and PrescribeWellness, its patient communication-pharmacy enablement application. Through its OutcomesOne™ platform, Outcomes offers a portfolio of patient engagement, clinical care, workflow, and financial solutions.

    The combined organization will expand upon TDS's existing solutions for delivering clinical care, medication therapy management and diversifying pharmacy revenue streams by adding Outcomes' digital capabilities for patient engagement, virtual verification, order grouping, pill counting, and financial insights. Together, TDS and Outcomes will create additional opportunities for pharmacists to participate in sponsored clinical interventions and better access for payors and pharmaceutical companies to drive better care and outcomes for patients.

    "This is an exciting new chapter for our Outcomes business, reflecting our continued commitment to pharmacies as trusted, community healthcare destinations," said Debbie Weitzman, CEO of Cardinal Health's pharmaceutical segment. "Bringing together the powerful connections and unified platform of Outcomes with TDS's best-in-class pharmacy management solutions will enable pharmacies to offer an elevated level of personal care for their patients, operate more effectively and achieve even better clinical and financial results." 

    "Adding Outcomes to TDS's platform represents a major milestone for optimizing care delivery and maximizing clinical reimbursement in the pharmacy," said Jude Dieterman, CEO of Transaction Data Systems. "Together we can drive more meaningful connections with payers and pharma companies to improve adherence and health outcomes through streamlined programs in pharmacy workflow directly at the point of care."

    The transaction is anticipated to close, subject to customary closing conditions and the expiration or termination of regulatory periods, in the third calendar quarter of 2023. Jones Day is serving as legal advisor to Cardinal Health. SVB Securities is acting as financial advisor and Simpson Thacher & Bartlett LLP is serving as legal advisor to Transaction Data Systems.

    About Cardinal Health   

    Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With more than 50 years in business, operations in more than 30 countries and approximately 46,500 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com.

    About Transaction Data Systems 

    For over 45 years, TDS has been dedicated to the success of the pharmacy market and pharmacy supply chain. With its portfolio of products and services including Rx30, Computer-Rx, and PrescribeWellness, TDS provides innovative patient-centric technology solutions and pharmacy management systems to the pharmacy industry. We proudly support one of the largest install base of independent pharmacies in the industry with systems in all 50 states and the Virgin Islands. TDS is a leading provider of pharmacy-focused, patient-centric solutions. For more information, please visit tdsclinical.com. 

    About BlackRock LTPC 

    BlackRock LTPC is an innovative private equity strategy focused on investing in high-quality businesses and value creation through active collaboration with management teams. The strategy's flexible duration and prudent approach to leverage preserve optionality for growth and help enable compounded capital appreciation. LTPC's team of 21 professionals are based in New York and London and invest across North America and Western Europe. LTPC is backed by BlackRock, Inc., which manages $320 billion in alternative investments and commitments on behalf of clients worldwide as of March 31, 2023. For additional information on BlackRock, please visit www.blackrock.com/corporate. 

    About GTCR

    Founded in 1980, GTCR is a leading private equity firm that pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors. Since its inception, GTCR has invested more than $24 billion in over 270 companies, and the firm currently manages more than $35 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com.

    Contacts 

    Cardinal Health

    Media: Erich Timmerman - [email protected], 614.757.8231

    Investors: Kevin Moran - [email protected], 614.757.7942

    BlackRock: Christopher Beattie, [email protected], 646.231.8518

    Transaction Data Systems: Tycene Fritcher, [email protected], 813.786.1136

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cardinal-health-announces-the-merger-of-its-outcomes-business-into-transaction-data-systems-and-related-partnership-301842194.html

    SOURCE Cardinal Health

    Get the next $CAH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAH

    DatePrice TargetRatingAnalyst
    1/9/2026Neutral → Buy
    Citigroup
    12/9/2025$243.00Overweight
    Barclays
    6/3/2025$179.00Equal Weight → Overweight
    Wells Fargo
    2/5/2025$140.00 → $150.00Hold → Buy
    Jefferies
    1/8/2025$130.00 → $144.00Hold → Buy
    TD Cowen
    1/7/2025$140.00In-line → Outperform
    Evercore ISI
    1/6/2025$132.00 → $145.00Neutral → Buy
    BofA Securities
    12/13/2024$101.00 → $127.00Underweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $CAH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cardinal Health Reports Second Quarter Fiscal Year 2026 Results and Raises Outlook

    Revenue increased 19% to $65.6 billionGAAP1 operating earnings increased 29% to $707 million; GAAP diluted EPS increased 19% to $1.97Non-GAAP operating earnings increased 38% to $877 million; non-GAAP diluted EPS increased 36% to $2.63Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance2 to $10.15 to $10.35Cardinal Health completes annual baseline share repurchase of $750 millionCardinal Health reaches targeted leverage range3DUBLIN, Ohio, Feb. 5, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported second quarter fiscal year 2026 revenues of $65.6 billion, an increase of 19% from the second quarter of fiscal year 2025. Second quarter GAAP operating earnings increased 29%

    2/5/26 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Raises Fiscal 2026 Outlook and Highlights Strategic Progress During J.P. Morgan Healthcare Conference Presentation

    Raising Fiscal 2026 Outlook: Cardinal Health is increasing expectations for fiscal year 2026 non-GAAP diluted earnings per share (EPS)1 to at least $10.00, from its prior guidance range of $9.65 to $9.85Accelerating Specialty Growth: The company expects that its Specialty revenues will surpass $50 billion in fiscal 2026, marking a 16% compounded annual growth rate (CAGR) over three years2Successfully Navigating IRA Changes: The company confirms the successful transition of its manufacturer distribution service agreements for all branded pharmaceutical products impacted by the 2026 Medicare Drug Price Negotiation ProgramIntroducing ContinuCare™ Pathway: The company's direct-to-patient at-Home

    1/13/26 6:50:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health to Announce Second-Quarter Results for Fiscal Year 2026 on February 5

    DUBLIN, Ohio, Jan. 6, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) plans to release second-quarter financial results for its fiscal year 2026 on February 5, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern. To access the webcast and corresponding slide presentation, visit Cardinal Health's Investor Relations page. No access code is required. Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months. About Cardinal Health Cardinal

    1/6/26 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Human Resources Officer Pitteroff Valerie Christine was granted 3,982 shares, increasing direct ownership by 99% to 8,022 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    1/20/26 7:21:53 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    New insider Pitteroff Valerie Christine claimed ownership of 4,503 shares (SEC Form 3)

    3 - CARDINAL HEALTH INC (0000721371) (Issuer)

    1/7/26 4:10:22 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form 4 filed by Cardinal Health Inc.

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    12/2/25 4:11:52 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cardinal Health upgraded by Citigroup

    Citigroup upgraded Cardinal Health from Neutral to Buy

    1/9/26 8:24:26 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Barclays initiated coverage on Cardinal Health with a new price target

    Barclays initiated coverage of Cardinal Health with a rating of Overweight and set a new price target of $243.00

    12/9/25 8:43:24 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Cardinal Health from Equal Weight to Overweight and set a new price target of $179.00

    6/3/25 7:24:57 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    SEC Filings

    View All

    SEC Form 10-Q filed by Cardinal Health Inc.

    10-Q - CARDINAL HEALTH INC (0000721371) (Filer)

    2/5/26 8:47:09 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CARDINAL HEALTH INC (0000721371) (Filer)

    2/5/26 6:47:19 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CARDINAL HEALTH INC (0000721371) (Filer)

    1/13/26 6:53:33 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Leadership Updates

    Live Leadership Updates

    View All

    After Major Oncology Conference, All Eyes Turn to Industry Innovation

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

    6/12/25 9:00:00 AM ET
    $CAH
    $CTOR
    $CTXR
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Carlisle Companies Announces Leadership Appointments

    Carlisle Companies Incorporated (NYSE:CSL) today announced the appointment of Christopher B. Gaskill as Vice President & General Counsel for the Company. In conjunction with this appointment, Scott C. Selbach will transition to a new role as Executive Vice President, Government Relations for the Company. Mr. Selbach will also remain Secretary of the Company. Both Mr. Gaskill and Mr. Selbach will report to Chris Koch, Carlisle's Chair, President & Chief Executive Officer. Prior to joining Carlisle, Mr. Gaskill served as Executive Vice President, Chief Legal Officer, and Secretary at Summit Materials, Inc. (NYSE:SUM), where he was responsible for the company's global legal functions and ensu

    5/16/25 4:05:00 PM ET
    $CAH
    $CSL
    $SUM
    Other Pharmaceuticals
    Health Care
    Specialty Chemicals
    Industrials

    Robert Musslewhite and Sudhakar Ramakrishna to join Cardinal Health Board of Directors

    DUBLIN, Ohio, March 10, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert Musslewhite, former Chief Executive Officer of Definitive Healthcare Corp., and Sudhakar Ramakrishna, President and Chief Executive Officer of SolarWinds Corporation, as independent directors, effective March 7, 2025. With more than 20 years of leadership experience, including serving as CEO for two publicly traded companies, Mr. Musslewhite brings to the board unique expertise in advanced analytics, data, and technology across the healthcare e

    3/10/25 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Financials

    Live finance-specific insights

    View All

    Cardinal Health Reports Second Quarter Fiscal Year 2026 Results and Raises Outlook

    Revenue increased 19% to $65.6 billionGAAP1 operating earnings increased 29% to $707 million; GAAP diluted EPS increased 19% to $1.97Non-GAAP operating earnings increased 38% to $877 million; non-GAAP diluted EPS increased 36% to $2.63Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance2 to $10.15 to $10.35Cardinal Health completes annual baseline share repurchase of $750 millionCardinal Health reaches targeted leverage range3DUBLIN, Ohio, Feb. 5, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported second quarter fiscal year 2026 revenues of $65.6 billion, an increase of 19% from the second quarter of fiscal year 2025. Second quarter GAAP operating earnings increased 29%

    2/5/26 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Nov. 4, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on January 15, 2026 to shareholders of record at the close of business on January 2, 2026. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of

    11/4/25 4:45:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Reports First Quarter Fiscal Year 2026 Results and Raises Outlook

    Revenue increased 22% to $64 billionGAAP1 operating earnings increased 18% to $668 million; GAAP diluted EPS increased 11% to $1.88Non-GAAP operating earnings increased 37% to $857 million, driven by segment profit growth across all five of the company's operating segments; non-GAAP diluted EPS increased 36% to $2.55Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance2 to $9.65 to $9.85 and fiscal year 2026 non-GAAP adjusted free cash flow outlook to $3.0 to $3.5 billionCardinal Health anticipates completing the acquisition of Solaris Health in early NovemberDUBLIN, Ohio, Oct. 30, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported first quarter fiscal year 2026 revenues

    10/30/25 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    2/13/24 5:01:02 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    1/30/24 1:39:03 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    2/14/23 12:37:58 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care